Ameritas Investment Company’s AnaptysBio ANAB Stock Holding History

Ameritas Investment Company’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-75	Closed	-$3K	–	869
2019 Q3	$3K	Buy	+75	New	+$3.57K	﹤0.01%	1361

Other funds holding ANAB

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ameritas Investment Company's ANAB Position: Q4 2019 in Review

Ameritas Investment Company sold out of AnaptysBio (ANAB) in Q4 2019, closing a stake of 75 shares — an estimated $3K sold.

Ameritas Investment Company first reported a position in ANAB in Q3 2019 and held it in 1 quarter. The position peaked at $3K in Q3 2019. 121 funds tracked by Wall St. Rank hold ANAB as of Q4 2019.

Ameritas Investment Company reported no remaining AnaptysBio position as of Q4 2019 after selling out during the quarter.
Ameritas Investment Company sold 75 AnaptysBio shares in Q4 2019, an estimated $3K.
Ameritas Investment Company first reported a position in AnaptysBio in Q3 2019 and held it in 1 quarter.
Ameritas Investment Company's AnaptysBio position peaked at $3K in Q3 2019.
121 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2019.

Based on Ameritas Investment Company's 13F filing for Q4 2019, filed 18 Feb 2020.